Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|April 25, 2024

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistance prostate cancer.

Episodes in this series

Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"

EP. 1 Metastatic Prostate Cancer: Background and Patient Prognosis

Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"

EP. 2 Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"

EP. 3 Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life

Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"

EP. 4 Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"

EP. 5 Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"

EP. 6 Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"

EP. 7 Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Trending on Urology Times

The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD

FDA approves sildenafil oral film for men with erectile dysfunction

Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD

Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC

URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues